Pharmacology and Pharmacotherapy

  • Dietmar P. Berger
  • Rupert Engelhardt
  • Hartmut Henß
  • Jürgen Scheele
  • Claudia I. Müller
  • Alexandra Göbel
  • Beate Lubrich
  • Anna-Katharina Kaskel
  • Hendrik Veelken
  • Karin Potthoff
  • Ralph Waesch
  • Uwe Martens
  • Claudia Schmoor
  • Herbert Maier-Lenz
  • Antonia Müller


Breast Cancer Ovarian Cancer Endometrial Cancer Optic Neuritis Polycythemia Vera 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anderson CM. Drug profiles. In: Perry MC, Anderson CM, Doll DC et al. (eds) Companion Handbook to the Chemotherapy Sourcebook, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, 2004, pp 419–72Google Scholar
  2. 2.
    Chauncey TR. Drug resistance mechanisms in acute leukemia. Curr Opin Oncol 2001;13:21–6PubMedCrossRefGoogle Scholar
  3. 3.
    Egorin MJ. Overview of recent topics in clinical pharmacology of anticancer agents. Cancer Chemother Pharmacol 1998;42(Suppl):22–30CrossRefGoogle Scholar
  4. 4.
    Fischer DS, Knobf MT, Durivage HJ et al. The Cancer Chemotherapy Handbook. Mosby, Philadelphia, 2003, pp 48–241Google Scholar
  5. 5.
    Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 2000;60(Suppl 1):1–14PubMedCrossRefGoogle Scholar
  6. 6.
    Skeel RT. Antineoplastic drugs and biological response modifiers. Classification, use and toxicity of clinically useful agents. In: Skeel RT (ed) Handbook of Cancer Chemotherapy, 6th edn. Lippincott Williams & Wilkins, Philadelphia, 2003, pp 53–156Google Scholar
  7. 1. Drug Information, Information on Antineoplastic AgentsGoogle Scholar
  8. 2. Information on cytostaticsGoogle Scholar
  9. 3. Chemical Data BaseGoogle Scholar
  10. 1. Drug Information NetworkGoogle Scholar
  11. 2. Chemfinder DatabaseGoogle Scholar
  12. 3. Dose Calculation of CytostaticsGoogle Scholar
  13. 1.
    Ginsberg JP, Womer WB. Preventing organ-specific chemotherapy toxicity. Eur J Cancer 2005;41:2690–700PubMedCrossRefGoogle Scholar
  14. 2.
    Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474–85PubMedCrossRefGoogle Scholar
  15. 1. Drug informationGoogle Scholar
  16. 2. Information on CytostaticsGoogle Scholar
  17. 1.
    Bailey BJ, Briars GL. Estimating the surface area of the human body. Stat Med 1996;15:1325–32PubMedCrossRefGoogle Scholar
  18. 2.
    Baker SD, Verweij J, Rowinsky EK et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002;94:883–8Google Scholar
  19. 3.
    Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep 1970;54:225–35PubMedGoogle Scholar
  20. 4.
    Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987;317:1098PubMedGoogle Scholar
  21. 5.
    Reilly JJ, Workman P. Normalization of anti-cancer drug dosage using body weight and surface area: is it worthwhile? Cancer Chemother Pharmacol 1993;32:411–8PubMedCrossRefGoogle Scholar
  22. 1. BSA, Formulas and CommentsGoogle Scholar
  23. 2. BSA CalculationGoogle Scholar
  24. 3. BSA CalculationGoogle Scholar
  25. 1.
    Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 1998;56:1019–38PubMedCrossRefGoogle Scholar
  26. 2.
    Donelli MG, Zucchetti M, Munzone E et al. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998;34:33–46PubMedCrossRefGoogle Scholar
  27. 3.
    Ibrahim S, Honig P, Huang SM et al. Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives. J Clin Pharmacol 2000;40:31–8PubMedCrossRefGoogle Scholar
  28. 4.
    Lichtman SM, Villani G. Chemotherapy in the elderly: pharmacologic considerations. Cancer Control 2000;7:548–56PubMedGoogle Scholar
  29. 5.
    Marx GM, Blake GM, Galani E et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004;15:291–5PubMedCrossRefGoogle Scholar
  30. 6.
    Stevens LA, Coresh J, Greene Tet al. Assessing kidney function – measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473–83PubMedCrossRefGoogle Scholar
  31. 1. Drug Information (with specialist information)Google Scholar
  32. 2. Data Base of Chemical CompoundsGoogle Scholar
  33. 3. Information on CytostaticsGoogle Scholar
  34. 4. IBW calculatorGoogle Scholar
  35. 5. Creatinine Clearance CalculatorGoogle Scholar
  36. 6. GFR calculatorGoogle Scholar
  37. 1.
    Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol 2004;15:146–50PubMedCrossRefGoogle Scholar
  38. 2.
    Giacalone PL, Laffargue F, Benos P. Chemotherapy for breast carcinoma during pregnancy. A French national survey. Cancer 1999;86:2266–72PubMedCrossRefGoogle Scholar
  39. 3.
    Loibl S, von Minckwitz G, Gwyn K et al. Breast carcinoma during pregnancy. Cancer 2006; 106:237–46PubMedCrossRefGoogle Scholar
  40. 4.
    Partridge AH, Garber JE. Long-term outcomes of children exposed to antineoplastic agents in utero. Semin Oncol 2000;27:712–26PubMedGoogle Scholar
  41. 5.
    Salooja N, Szydio RM, Socie G et al. Pregnancy outcomes after peripheral blood or marrow transplantation: a retrospective survey. Lancet 2001;358:271–6PubMedCrossRefGoogle Scholar
  42. 6.
    Williams SF, Schilsky RL. Antineoplastic drugs administered during pregnancy. Semin Oncol 2000;27:618–22PubMedGoogle Scholar
  43. 1. NCI CancernetGoogle Scholar
  44. 2. SOGC GuidelineGoogle Scholar
  45. 1.
    Trissel LA. Handbook on Injectable Drugs, 14th edn. American Society of Health-System Pharmacists, Bethesda, 2007.Google Scholar
  46. 1. Drug Information (with specialist information)Google Scholar
  47. 2. Database of Chemical CompoundsGoogle Scholar
  48. 3. Internet Drug IndexGoogle Scholar
  49. 4. Information on CytostaticsGoogle Scholar
  50. 1.
    ASCO. Criteria for facilities and personnel for the administration of parenteral systemic antineoplastic therapy. J Clin Oncol 2004;22:4613–5CrossRefGoogle Scholar
  51. 2.
    Connor TH, McDiarmid MA. Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin 2006;56:354–65PubMedCrossRefGoogle Scholar
  52. 3.
    Trissel LA. Handbook on Injectable Drugs, 14th edn. American Society of Health-System Pharmacists, Betherda, 2007Google Scholar
  53. 1. Drug InformationGoogle Scholar
  54. 2. Information on CytostaticsGoogle Scholar
  55. 1.
    Boekhout AH, Beijnen JH, Schellens JHM. Symptoms and treatment in cancer therapy-induced early menopause. Oncologist 2006;11:641–54PubMedCrossRefGoogle Scholar
  56. 2.
    Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol 2003;30(suppl 14):3–11PubMedCrossRefGoogle Scholar
  57. 3.
    Smith RE. A review of Selective Estrogen Receptor Modulators and National Surgical Adjuvant Breast and Bowel Projects clinical trials. Semin Oncol 2003;30(suppl 16):4–13PubMedCrossRefGoogle Scholar
  58. 4.
    Writing Group for the Women’s Health Initiative (WHI) Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321–33CrossRefGoogle Scholar
  59. 5.
    Zlotta AR, Schulman CC. Neoadjuvant and adjuvant hormone therapy for prostate cancer. World J Urol 2000;18:179–82PubMedCrossRefGoogle Scholar
  60. 1. Hormone Therapy in Prostate CancerGoogle Scholar
  61. 2. Hormone Therapy in Testicular TumorsGoogle Scholar
  62. 3. American Association of Clinical EndocrinologistsGoogle Scholar
  63. 4.
Hellstrom2.html Testosterone Replacement TherapyGoogle Scholar
  64. 1.
    Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10(18 Pt 2):6342S–6SPubMedCrossRefGoogle Scholar
  65. 2.
    Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004;4:314–20PubMedCrossRefGoogle Scholar
  66. 3.
    Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11–22PubMedCrossRefGoogle Scholar
  67. 4.
    Morcellin S, Rossi CR, Pilati P et al. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth factor Rev 2005;16:35–53CrossRefGoogle Scholar
  68. 5.
    Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8–32PubMedCrossRefGoogle Scholar
  69. 1. International Cytokine SocietyGoogle Scholar
  70. 2. Cytokines JournalGoogle Scholar
  71. 3. Cytokine Growth Factor ReviewsGoogle Scholar
  72. 4. Cytokine Family DatabaseGoogle Scholar
  73. 1.
    Baselga J. Monoclonal antibodies directed at growth factor receptors. Ann Oncol 2000;11(suppl 3):187–90PubMedCrossRefGoogle Scholar
  74. 2.
    Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. J Clin Oncol 2005;23:3235–42PubMedCrossRefGoogle Scholar
  75. 3.
    Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011–27PubMedCrossRefGoogle Scholar
  76. 4.
    Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341–54PubMedCrossRefGoogle Scholar
  77. 5.
    López-Guillermo A, Mercadal S. The clinical use of antibodies in haematological malignancies. Ann Oncol 2007;18 ( Suppl. 9): ix51–7PubMedCrossRefGoogle Scholar
  78. 6.
    Plosker G, Figgitt, D. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 2003, 63:803–43PubMedCrossRefGoogle Scholar
  79. 7.
    Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeuties. Nat Rev Drug Discov 2007;6:349–355PubMedCrossRefGoogle Scholar
  80. 8.
    Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol 2003;30:424–33PubMedCrossRefGoogle Scholar
  81. 1. Oncolink InformationGoogle Scholar
  82. 2. American Cancer SocietyGoogle Scholar
  83. 3. National Cancer Institute, Bethesda, USAGoogle Scholar
  84. 4. FDA, Center for Biologics Evaluation and ResearchGoogle Scholar
  85. 5. Monoclonal Antibody IndexGoogle Scholar
  86. 6.
biologicaltherapies/monoclonalantibodies Cancer Backup UKGoogle Scholar
  87. 7.
monoclonal_antibodies Wikipedia, Monoclonal AntibodiesGoogle Scholar
  88. 1.
    Bells HS, Ryan KM. Intracellular signalling and cancer: complex pathways lead to multiple targets. Eur J Cancer 2005;41:206–15CrossRefGoogle Scholar
  89. 2.
    Benson C, Kaye S, Workman P et al. Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br J Cancer 2005;92:7–12PubMedCrossRefGoogle Scholar
  90. 3.
    Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640–53PubMedCrossRefGoogle Scholar
  91. 4.
    Ghobrial IM, Witzig TE, Adjej AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005;55:178–94PubMedGoogle Scholar
  92. 5.
    Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. J Clin Oncol 2005;23:3235–42PubMedCrossRefGoogle Scholar
  93. 6.
    Lancet JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 2003;102:2880–9CrossRefGoogle Scholar
  94. 7.
    Nencioni A, Grünebach F, Patrone F et al. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007;21:20–6CrossRefGoogle Scholar
  95. 8.
    Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505–18PubMedCrossRefGoogle Scholar
  96. 9.
    Sabatini DM. mTOR and cancer. Nat Rev Cancer 2006;6:729–34PubMedCrossRefGoogle Scholar
  97. 1. National Cancer InstituteGoogle Scholar
  98. 2. Nature Reviews CancerGoogle Scholar
  99. 3. Oncolink “Targeted Therapies”Google Scholar
  100. 4. FDA, Glivec InformationGoogle Scholar
  101. 1.
    Dixon JR. The International Conference on Harmonization Good Clinical Practice Guideline. Qual Assur 1998;6:65–74PubMedGoogle Scholar
  102. 2.
    EEC note for guidance: good clinical practice for trials on medicinal products in the European Community. CPMP Party on Efficacy of Medicinal Products. Pharmacol Toxicol 1990;67:361–72Google Scholar
  103. 3.
    Gajic A, Herrmann R, Salzberg M. The international quality requirements for the conduct of clinical studies and the challenges for study centers to implement them. Ann Oncol 2004;15:1305–9PubMedCrossRefGoogle Scholar
  104. 4.
    Idanpaan-Heikkila JE. WHO guidelines for good clinical practice (GCP) for trials on pharmaceutical products: responsibilities of the investigator. Ann Med 1994;26:89–94PubMedCrossRefGoogle Scholar
  105. 5.
    World Medical Association. Helsinki Declaration, 1975. In: Beauchamp TL, Walters LW (eds) Contemporary Issues in Bioethics, 2nd edn. Wadsworth, Belmont, CA, 1982Google Scholar
  106. 1. European Clinical Trials DatabaseGoogle Scholar
  107. 2. US Clinical Trials DatabaseGoogle Scholar
  108. 3. Study RegisterGoogle Scholar
  109. 4. Clinical Trials Listing ServiceGoogle Scholar
  110. 5. EMEA, European Agency for Evaluation of Medicinal ProductsGoogle Scholar
  111. 6. FDA, Food and Drug Administration, USAGoogle Scholar
  112. 7. ICH, International Conf. HarmonizationGoogle Scholar
  113. 1.
    Dervieux T, Meshkin B, Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res 2005;31:90–105Google Scholar
  114. 2.
    Desai AA, Innocenti F, Ratain MJ. Pharmacogenomics: roads to anticancer therapeutics nirvana? Oncogene 2003;22:6621–8PubMedCrossRefGoogle Scholar
  115. 3.
    Lee W, Lockhart AC, Kim RM et al. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 2005;10:104–11PubMedCrossRefGoogle Scholar
  116. 4.
    Loni L, De Braud F, Zinzani PL et al. Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin’s lymphoma. Leuk Lymphoma 2003;44(suppl 3):S115–22PubMedCrossRefGoogle Scholar
  117. 5.
    Marsh S. Pharmacogenomics. Ann Oncol 2007;18(suppl 9):ix24–8PubMedCrossRefGoogle Scholar
  118. 6.
    Stam RW, den Boer ML, Meijerink JP et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003;101:1270–6PubMedCrossRefGoogle Scholar
  119. 7.
    Tan BR, McLeod HL. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Semin Oncol 2005;32:113–9PubMedCrossRefGoogle Scholar
  120. 8.
    Weinshilboum R, Wand L. Pharmacogenomics: from bench to bedside. Nat Rev Drug Discovery 2004;3:739–48CrossRefGoogle Scholar
  121. 1.
    http:// Pharmacogenomics JournalGoogle Scholar
  122. 2. Pharmacogenomics PrimerGoogle Scholar
  123. 3. Pharmacogenetics DatabaseGoogle Scholar
  124. 4. Pharmacogenetics Research NetworkGoogle Scholar
  125. 5. SNP ConsortiumGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Dietmar P. Berger
    • 1
  • Rupert Engelhardt
    • 2
  • Hartmut Henß
    • 1
  • Jürgen Scheele
    • 3
  • Claudia I. Müller
    • 3
  • Alexandra Göbel
    • 1
  • Beate Lubrich
    • 4
  • Anna-Katharina Kaskel
    • 1
  • Hendrik Veelken
    • 3
  • Karin Potthoff
    • 5
  • Ralph Waesch
    • 1
  • Uwe Martens
    • 1
  • Claudia Schmoor
    • 6
  • Herbert Maier-Lenz
    • 6
  • Antonia Müller
    • 1
  1. 1.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  2. 2.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  3. 3.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  4. 4.Hospital PharmacyUniversity Medical CenterFreiburgGermany
  5. 5.Department of Translational OncologyNational Center for Tumor Diseases Heidelberg(NCT)HeidelbergGermany
  6. 6.Center of Clinical TrialsUniversity Medical CenterFreiburgGermany

Personalised recommendations